

RESEARCH ARTICLE

Open Access



Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization

Andrea Negro^{1,2}, Jessica L. Seidel¹, Thijs Houben¹, Esther S. Yu¹, Ike Rosen¹, Andrea J. Arreguin¹, Nilufer Yalcin¹, Lea Shorser-Gentile¹, Lea Pearlman¹, Homa Sadhegian¹, Ramalingam Vettrivelan³, Nancy L. Chamberlin⁴, Cenk Ayata^{1,5}, Paolo Martelletti², Michael A. Moskowitz⁶ and Katharina Eikermann-Haerter^{1,7*} 

Abstract

Background: Migraine is a common headache disorder, with cortical spreading depolarization (CSD) considered as the underlying electrophysiological event. CSD is a slowly propagating wave of neuronal and glial depolarization. Sleep disorders are well known risk factors for migraine chronification, and changes in wake-sleep pattern such as sleep deprivation are common migraine triggers. The underlying mechanisms are unknown. As a step towards developing an animal model to study this, we test whether sleep deprivation, a modifiable migraine trigger, enhances CSD susceptibility in rodent models.

Methods: *Acute* sleep deprivation was achieved using the “gentle handling method”, chosen to minimize stress and avoid confounding bias. Sleep deprivation was started with onset of light (diurnal lighting conditions), and assessment of CSD was performed at the end of a 6 h or 12 h sleep deprivation period. The effect of *chronic* sleep deprivation on CSD was assessed 6 weeks or 12 weeks after lesioning of the hypothalamic ventrolateral preoptic nucleus. All experiments were done in a blinded fashion with respect to sleep status. During 60 min of continuous topical KCl application, we assessed the total number of CSDs, the direct current shift amplitude and duration of the first CSD, the average and cumulative duration of all CSDs, propagation speed, and electrical CSD threshold.

Results: *Acute* sleep deprivation of 6 h ($n = 17$) or 12 h ($n = 11$) duration significantly increased CSD frequency compared to controls (17 ± 4 and 18 ± 2 , respectively, vs. 14 ± 2 CSDs/hour in controls; $p = 0.003$ for both), whereas other electrophysiological properties of CSD were unchanged. *Acute* total sleep deprivation over 12 h but not over 6 h reduced the electrical threshold of CSD compared to controls ($p = 0.037$ and $p = 0.095$, respectively). *Chronic* partial sleep deprivation in contrast did not affect CSD susceptibility in rats.

(Continued on next page)

* Correspondence: khaerter@mgh.harvard.edu

¹Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA

⁷Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusions: *Acute* but not *chronic* sleep deprivation enhances CSD susceptibility in rodents, possibly underlying its negative impact as a migraine trigger and exacerbating factor. Our findings underscore the importance of CSD as a therapeutic target in migraine and suggest that headache management should identify and treat associated sleep disorders.

Keywords: Cortical spreading depolarization, CSD, Migraine, Sleep deprivation, Ventrolateral preoptic (VLPO) nucleus, VLPO

Introduction

Migraine is a multifactorial neurovascular disorder characterized by recurrent episodes of headache. One third of patients experience transient neurological symptoms associated with their attacks, the so-called migraine aura. Migraine is among the most common neurological diseases, affecting approximately 20% of the adult population [1]. The socioeconomic impact is high [2, 3], and the World Health Organization recognized migraine as a major public health problem by ranking it as #2 among all diseases causing disability [4] and as #1 in under-50-year-old humans of both genders [5]. Migraine attacks may increase in frequency over time, and approximately 2.5% of patients with episodic migraine develop chronic migraine [6]. The transition to more frequent attack patterns is influenced by genetic predisposition, co-morbid conditions, life events and lifestyle [7].

Sleep disorders are well known risk factors for migraine chronification [7, 8] and changes in wake-sleep patterns such as sleep deprivation are common migraine triggers [9]. Compared to a few decades ago, adults sleep less, and sleeping as little as possible is often seen as an admirable behavior. Sleep loss may result from total sleep deprivation (such as shift workers might experience), chronic sleep restriction (due to work, medical conditions or lifestyle), or sleep disruption (in sleep disorders such as sleep apnea or restless legs syndrome) [10]. Sleep disorders are frequently observed in specific headache diagnoses (e.g., migraine, tension-type headache, cluster headache) [11] and other nonspecific headache patterns (i.e., chronic daily headache, hypnic headache, “awakening” or morning headache) [12]. In migraineurs, sleep disorders are well known predictive factors of progression from episodic to chronic forms [13]. In contrast, a targeted behavioral sleep intervention can lead to an improvement in headache frequency and reversion from chronic to episodic migraine [14]. The sleep deprivation-induced increase in adenosine levels might be an underlying mechanism, because adenosine levels are elevated during migraine attacks, and administration of adenosine can precipitate migraine attacks [15].

Cortical spreading depolarization (CSD), discovered by Leão in 1944 [16], is considered the electrophysiological correlate of migraine aura, and a possible trigger of

migraine headache [17]. CSD is an intense propagating depolarization of neuronal and glial membranes. Evoked when the local extracellular potassium concentration $[K^+]_e$ exceeds a critical threshold, CSD causes a loss of membrane resistance and massive ionic disturbances with cell swelling. Genetic and environmental factors important for the clinical manifestation of migraine have been shown to modulate cortical excitability, including the potential to elevate $[K^+]_e$ and glutamate to levels sufficient to initiate and facilitate CSD. For example, mutations causing the migraine-associated syndromes familial hemiplegic migraine (FHM) or cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) enhance CSD susceptibility [18, 19]. Similarly, gonadal hormones modulate CSD susceptibility, to explain the female preponderance in migraine [18, 20]. In the setting of sleep deprivation, adenosine overload with overstimulation of A₁ receptors is a possible mechanism modulating neuronal activity and CSD, because adenosine A₁ receptor activation contributes to the persistent secondary phase of Leão’s cortical spreading depression [21, 22].

The current study found that *acute* sleep deprivation as a modifiable environmental factor enhances CSD susceptibility, possibly explaining its debilitating effects on migraine.

Materials and methods

Experimental groups

All experimental procedures were carried out in accordance with the Guide for Care and Use of Laboratory Animals (NIH Publication No. 85–23, 1996), and were approved by the institutional review board (MGH Subcommittee on Research Animal Care, SRAC) and Institutional Animal Use and Care Committee of Beth Israel Deaconess Medical Center. All animals were housed individually under controlled conditions (12 h of light starting at 08:00) in an isolated ventilated chamber maintained at 20–22 °C and given access to food and water ad libitum. Only male rodents were used in this study to reduce the number of animals needed to control for hormonal fluctuations during the female estrus cycle [23]. CSD recordings were carried out by an investigator blinded to the sleep deprivation status.

a) *Acute Sleep Deprivation:*

A total of 58 rats (Sprague-Dawley, male, 340 ± 40 g; Charles River Laboratories, Wilmington, MA) were used to test the hypothesis that acute sleep deprivation enhances CSD susceptibility. Experimental groups consisted of 30 control rats as well as 11 rats after 12 h of sleep deprivation and 17 rats after 6 h of sleep deprivation. From the group of 30 control rats, we used 11 rats as controls interleaved with rats after 6 h of sleep deprivation and 19 rats as controls interleaved with rats after 12 h of sleep deprivation. Acute sleep deprivation was induced using the “gentle handling method” [24], chosen to minimize stress and avoid any confounding bias associated with enforced waking present with other techniques (e.g. lights, sounds, water tank). For the same reason, the “gentle handling method” was preferred over alternative techniques that use stimuli known to also serve as migraine triggers, e.g., stress, pain, light, smell or sound [25], which could have introduced additional confounding bias. Rats were kept awake by providing new objects into their home cage when they adopted a sleeping posture, i.e., curled up with eyes closed. Sleep deprivation was started with the onset of light cycle (diurnal lighting conditions, 8 am - 8 pm), and assessment of CSD was performed at the end of the 6 h or 12 h sleep deprivation period. Control rats were kept in the same environment but left undisturbed. Sleep-deprived rats and control rats were housed individually, in the same room. Every day, one control rat and one sleep-deprived rat were randomized and coded with the letter “A” or “B” on their cage card, by a person not involved in CSD recordings. The investigator performed 2 CSD recordings per day, testing 1 control rat and 1 sleep-deprived rat, in random order. The investigator pulled a card with “A” or “B” before CSD recordings, and started CSD recordings with the respective rat accordingly, not knowing the rat’s sleep deprivation status.

b) *Chronic sleep deprivation*

A total of 29 rats (Sprague-Dawley, male, 405 ± 30 g; Taconic, Germantown, NY) were used to test the effect of partial chronic sleep deprivation on CSD susceptibility. To minimize stress and avoid any confounding bias associated with enforced waking, chronic sleep deprivation was induced by cytotoxic lesioning of the hypothalamic sleep-promoting cell group, the ventrolateral preoptic (VLPO) nucleus [26]. All rats were implanted with electrodes for recording electroencephalogram (EEG) and electromyogram (EMG) for assessing their sleep-wake status. A pre-lesion control EEG of the rats was continuously

recorded for 24 h (13:00–13:00), 6 days after the EEG implantation. Wake–sleep states were manually scored, by an observer who was not aware of the histological results of the animals, in 12 s epochs based on the digitized EEG of each rat. Wakefulness was identified by the presence of desynchronized-EEG.

Animals were anesthetized with chloral hydrate and positioned in a stereotaxic frame. The skull was reexposed, and the tip of a fine glass micropipette was placed at the VLPO stereotaxic coordinates (AP -0.6 from bregma, L ± 1.00 , DV 8.5 as per the rat atlas of Paxinos and Watson). Two hundred nanoliters of 0.1% orexin-B-saporin (Advanced Targeting Systems, CA, USA) or saline as a control were injected by air pressure and the pipette was slowly removed after 2 min. In this manner, each rat received bilateral injections targeted at the VLPO. Two weeks after the surgical procedure, rats were habituated to the recording conditions and sleep-wake recordings (EEG/EMG) were performed for 24 h. In order to assess the cumulative effect of chronic sleep deprivation, CSD recordings (as described below) were performed 6 weeks or 12 weeks after VLPO lesions. Following CSD characterization, rats were perfused with saline (100 ml) followed by 10% formalin (300 ml) transcardially and their brains were cut in the coronal plane on a freezing microtome into four evenly spaced series of 40 μ m coronal sections and Nissl stained as described previously [26, 27]. VLPO lesioning was considered successful in cases of $>70\%$ VLPO neuron loss bilaterally, which has been shown repeatedly in multiple studies to cause a 50% decrease in NREM sleep time [26]. The control group consists of rats with off-target lesions, and sham-lesioned (saline-injected) rats.

Surgical preparation for CSD assessment

Rodents were anesthetized with isoflurane (2.5% induction, 1% maintenance, in 70% N₂O / 30% O₂), and tracheostomized for mechanical ventilation (SAR-830, CWE, Ardmore, PA, USA). A femoral artery was cannulated for continuous mean arterial blood pressure recording (PowerLab; AD Instruments, Colorado Springs, CO, USA). Arterial blood gas and pH were maintained within normal limits by adjusting the ventilation parameters (Rapidlab 248 blood gas/pH analyzer, Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Rectal temperature was maintained at 36–37 degrees Celsius using a thermostatically controlled heating pad (FHC, Bowdoinham, ME, USA). Rodents were placed in a stereotaxic frame (Stoelting, Wood Dale, IL, USA) and 3 burr holes were drilled bilaterally for electrophysiological recordings (recording site 2), as described previously (Fig. 1) [28].




Fig. 1 Experimental setup for electrophysiological recordings. CSD, cortical spreading depolarization; E, electrode; μC , micro coulomb

Electrophysiological CSD recordings

All experiments were performed in a blinded fashion with respect to sleep status. Two glass capillary micro-electrodes were placed to measure the potential difference between recording sites 1 and 2 on each side of the brain to record extracellular steady (DC) potential changes and electrocorticogram (FHC, Inc. Bowdoinham, ME), using a data acquisition system for off-line analysis (PowerLab; AD Instruments, Colorado Springs, MO, USA). The electrical stimulation threshold for CSD was assessed by direct cortical stimulation with a bipolar stimulation electrode placed on the occipital cortex (400 μm tip diameter, 1 mm tip separation; Frederick Haer Company, Bowdoin, ME, USA). Using a stimulator (GrassInstruments, West Warwick, RI, USA) and a constant current unit (WPI, Sarasota, FL, USA), cathodal squared pulses of increasing intensity and duration (1–4000 μC) were applied at 4 min intervals, until CSD occurred. For KCl-induced CSD susceptibility, a 1.5 mm cotton ball soaked with 1 M KCl was placed on the pial surface of the contralateral hemisphere and replaced every 15 min. The total number of CSDs during 60 min of continuous topical KCl application was counted. The DC shift amplitude and duration (sec) (measured at half maximal amplitude) of the first CSD, as well as the propagation speed (mm/min), the propagation failure (%) and the cumulative duration (sec) of all CSDs during continuous KCl application were calculated.

Statistics

Data were analyzed with SPSS (version 11.0). Using a general linear model of covariance analysis (ANACOVA), we tested for an effect of the independent

variable sleep deprivation on the dependent variables CSD threshold, frequency and propagation speed. Other electrophysiological measures of CSD and systemic physiological data were compared among groups using one-way ANOVA. Data are shown as mean \pm standard deviation, and $p < 0.05$ was considered significant.

Results

Mean arterial blood pressure, arterial pCO_2 and pH were within normal physiological range and did not differ among groups (Table 1).

Acute sleep deprivation increased CSD susceptibility

Twelve hours but not 6 h sleep deprivation significantly reduced the electrical threshold for CSD induction,

Table 1 Physiological parameters

Group	pH	paCO2	paO2	BP
Control	7.41 \pm 0.03	42 \pm 2	117 \pm 18	83 \pm 9
6 h sleep deprivation	7.41 \pm 0.02	40 \pm 3	123 \pm 28	92 \pm 11
12 h sleep deprivation	7.41 \pm 0.03	39 \pm 2	119 \pm 22	89 \pm 8
Group	pH	paCO2	paO2	BP
VLPO-lesioned	7.42 \pm 0.04	39 \pm 6	132 \pm 21	99 \pm 12
Control	7.39 \pm 0.05	41 \pm 8	118 \pm 37	90 \pm 17

Physiological parameters did not differ between groups. A) Acute sleep deprivation in rats: 6 h controls and 12 h controls were pooled for statistical analysis, as no significant difference was found between the two control groups; B) Chronic sleep deprivation in VLPO-lesioned rats. Control animals underwent a sham procedure with saline injection into their VLPO. The arterial blood gas (mmHg) and pH values were measured at the beginning and end of each KCl stimulation period, and before electrical stimulation, for a total of 6 measurements per experiment. Data are presented as average \pm SD. Arterial blood pressure (BP) values (mmHg) are the average of the KCl application and electrical stimulation recording periods

when compared to controls ($p = 0.037$ and $p = 0.095$, respectively; Fig. 2). Data from 6 h and 12 h control animals were pooled as there were no differences for any study endpoint. Overall, sleep deprived rats showed a reduced electrical threshold of CSD compared to controls ($p = 0.015$) (Table 2). Continuous application of 1 M KCl on the occipital cortex evoked repetitive CSDs in all groups. Control rats ($n = 30$; 6 h and 12 h) developed 14.4 ± 2.0 CSDs/hour. Both 6 h ($n = 17$) and 12 h ($n = 11$) sleep-deprivation increased CSD frequency compared to respective-interleaved controls (16.9 ± 3.5 and 17.9 ± 2.1 , respectively; $p = 0.003$ for both; Fig. 3), while other electrophysiological properties of CSD were unchanged. Recordings from 6 h or 12 h sleep-deprived rats and controls did not differ for propagation speed (4.6 ± 0.7 , 4.5 ± 0.5 and 4.2 ± 0.6) and propagation failure (31.9 ± 13.2 , 30.0 ± 11.8 and 31.5 ± 11.8) (Table 3), neither for the duration of first CSD (23.4 ± 3.8 , 23.9 ± 5.1 and 23.1 ± 4.6) or cumulative CSD duration (292.6 ± 79.1 , 297.1 ± 48.1 and 267.6 ± 73.9) (Additional files: Figures 1 and 2). Direct cortical cathodal stimulation with stepwise escalating intensities and durations triggered CSD in all rats.

Chronic sleep deprivation did not affect CSD susceptibility

Histological analysis showed that VLPO lesioning reduced the number of intact VLPO neurons, as detailed in Fig. 4.

Table 2 Effect of acute sleep deprivation on CSD electrical threshold

Group	n	CSD Threshold (μC)	
		mean (range)	average \pm SD
Control	19	50 (1–800)	108 \pm 227
6 h sleep deprivation	11	20 (1–400)	63 \pm 116
12 h sleep deprivation	14	10 (1–300)*	41 \pm 76*
6 h and 12 h sleep deprivation	25	15 (1–400)*	50 \pm 93*

Sleep deprivation of 12 h but not 6 h decreased the electrical CSD threshold. All controls (6 h controls and 12 h controls) were pooled for statistical analysis, as no significant difference was found between the two control groups * $p < 0.01$ vs. control

Continuous topical KCl application evoked repetitive CSDs in all rats. There was no difference between VLPO lesioned rats and controls, and there was no correlation between the number of intact VLPO neurons and CSD electrical threshold (1100 ± 1295 vs. 767 ± 320 ; Fig. 4a), CSD frequency (10.5 ± 4.3 vs. 9.7 ± 4.1 ; Fig. 4b) or for any other CSD parameter (propagation speed: 3.0 ± 0.5 vs. 3.3 ± 0.8 ; duration of first CSD: 23.8 ± 7.8 vs. 26.3 ± 7.8 ; cumulative CSDs duration: 174.2 ± 72.8 vs. 175.1 ± 44.7) (Additional files: Figure 3a and b).

Discussion

We investigated the effect of sleep deprivation on CSD susceptibility, the electrophysiological correlate of




Fig. 2 Effect of acute sleep deprivation on electrical CSD threshold. CSD threshold was reduced after 12 h but not 6 h of sleep deprivation. Each circle represents the CSD threshold of an individual rat. All controls (6 h controls and 12 h controls) were pooled for statistical analysis, as no significant difference was found between the two control groups. * $p < 0.01$ vs. control

have been implicated in CSD susceptibility [46], and, thus, an increase in glutamatergic neurotransmission could explain the sleep deprivation-induced increase in CSD susceptibility. In addition, lack of sleep may enhance CSD susceptibility by inhibiting the Na^+/K^+ -ATPase in the setting of energy failure secondary to oxidative stress. The surge in adenosine triphosphate (ATP) levels, the energy currency of brain cells, occurs when neuronal activity is reduced, as during sleep. The levels of phosphorylated AMP-activated protein kinase (P-AMPK), important for cellular energy sensing and regulation, are lower during the sleep-induced ATP surge than during wake or sleep deprivation [47]. Accordingly, prolonged sleep deprivation significantly decreases the activity of anti-oxidative enzymes such as superoxide dismutase and glutathione peroxidase that regulate the level of reactive oxygen species [48] and has been shown to increase lipid peroxidation in the rat hippocampus, thalamus and hypothalamus, leading to a higher oxidative stress in these brain regions compared to others [49].

Another potential link between migraine, sleep deprivation and CSD is altered neurotransmitter dynamics. For example, adenosine has been implicated in migraine pathophysiology, because adenosine levels were shown to be elevated during migraine attacks and administration of adenosine can precipitate migraine attacks [15]. Moreover, the adenosine A2A receptor gene haplotype was found to be associated with migraine with aura [50]. Adenosine has been shown to be elevated after CSD in brain slices under conditions likely to trigger CSD in vivo, and adenosine receptor activation has been shown to be involved in the prolonged depression of synaptic transmission after CSD [51]. At the same time, a role for adenosine in sleep regulation has been suggested by studies showing a progressive increase in extracellular adenosine in the basal forebrain during prolonged wakefulness [52], possibly explaining the potential CSD-mediated negative effect of sleep deprivation on migraine.

The high prevalence of sleep disturbances in migraineurs could also depend in part on a dysregulation of the cyclic secretion of melatonin. During a migraine attack, the plasma levels of melatonin are decreased [53], and evidence suggests that administering melatonin to migraine sufferers relieves pain and decreases headache recurrence in some cases [54]. Accordingly, melatonin slows down retinal spreading depression [55] and can attenuate the process of trigeminovascular nociception induced by CSD in rats [56]. In addition, serotonergic processes have been implicated in mediating the migraine promoting effect of sleep deprivation. Serotonin is a neuromodulator with a pivotal role in regulating several central nervous system activities, including pain

threshold and sleep induction. Sleep deprivation causes an enhancement of serotonergic neurotransmission in the brain, as suggested in animal studies. In sleep-deprived rats, elevated serotonin levels have been measured in the hippocampus [57] and in serotonergic raphe nuclei [58], which, with their widespread cortical projections, are part of the monoaminergic wake promoting system. Accordingly, human in vivo studies showed that plasma levels of serotonin and its precursor tryptophan exhibit a significant increase during sleep deprivation compared to sleep [59] and that a single night of total sleep deprivation causes significant increases of serotonin 2A receptor binding potentials in a variety of cortical regions [60]. Future experiments could aim to clarify the role of melatonin and serotonin in mediating the effect of sleep deprivation on CSD, for example by testing if melatonin supplementation or anti-serotonergic drugs diminish or abrogate the sleep deprivation-induced increase in CSD susceptibility.

Recently, Kilic et al. reported that the enhanced susceptibility to CSD after sleep deprivation may be due to impaired K^+ and glutamate clearance by astrocytes consequent to sleep deprivation-induced suppression of glycogen use and synaptic energy substrate deficiency [61]. The authors demonstrated that sleep deprivation for 6 h using the same “gentle handling method” decreased threshold for CSD induction and prolonged the duration of CSDs without changing the CSD propagation speed and frequency, which, on the contrary, had increased in our experiments. Furthermore, this study reported that the decreased CSD thresholds could be recovered via the use of an alternate energy supply (D-glucose or L-lactate superfusion), linking decreased CSD thresholds to an activity/energy mismatch resulting from prolonged wakefulness [61]. An alternate energy supply was able to revert the enhancement of CSD susceptibility and reduced clearance of K^+ during synaptic activity. Differences between results of the Kilic study and ours could be attributed to species differences, because mice show a predominantly vasoconstrictive response to CSD, which is in contrast to the biphasic vascular response that is seen in humans or rats, used in our experiments. In addition, Kilic et al. administered urethane/xylazine as anesthetic, which has a different effect on cortical excitability than isoflurane, which was used in our study [62].

We also tested the effect of chronic sleep deprivation on CSD susceptibility in rats sustaining the loss of VLPO neurons, a previously validated model of chronic sleep restriction [26]. It is well established that the VLPO is a key sleep-promoting cell group in the hypothalamus, and, already in 1930, von Economo reported that lesions of this region cause prolonged insomnia in humans [63]. Neurons in the preoptic hypothalamus are important

regulators of sleep onset and sleep maintenance [64]. VLPO is thought to play a major role in causing sleep by GABAA receptor-mediated hyperpolarization and inhibition of histaminergic neurons in the tuberomammillary nucleus [65], which are important for promoting wakefulness [66]. VLPO lesions induce long-lasting insomnia in rats, with a 60–70% decrease in delta power and a 50–60% decrease in NREM sleep time [26]. VLPO lesion experiments allowed us to study the effect of chronic partial sleep loss on CSD without continual stressful experimental interventions, to avoid a possible confounding impact of stress on CSD. We here show that CSD susceptibility is not altered 6 weeks or 12 weeks after VLPO lesioning, suggesting that the effect of acute sleep deprivation on CSD is not mediated via reduced NREM sleep, that *acute total* sleep deprivation has a different effect on cortical excitability than *chronic partial* sleep restriction, and/or that compensatory mechanisms cause adaptation of cortical excitability within the *chronic* setting.

Our study has several limitations, including the fact that animal sleep deprivation models may not allow direct extrapolation to patients. However, gentle handling is very effective at inducing total sleep deprivation as determined by electroencephalography [67] and seems to be a valid model of typical sleep deprivation in humans. While the gentle handling method is less stressful than other methods that induce sleep deprivation, it still may be a cause of stress. It is therefore possible that the pathways induced by sleep deprivation in our animal model are different from those that occur in humans who consciously decide to stay awake or delay sleep. However, we feel that acute stress may not be important for our study endpoint, CSD susceptibility, as acute stress has recently been shown to not affect CSD susceptibility in rodents [68]. In addition, we used an invasive method to induce and record CSD, which may have affected our endpoint of CSD susceptibility. However, assessment of CSD susceptibility with electrocortical recordings, and CSD induction with KCl and electrical stimuli are the most established methods, used in many other respected studies in the field [17–19]. Another possible shortcoming is the fact that rats were anesthetized during CSD assessment, and it has been shown that anesthetics modify CSD threshold [62]. Future experiments could perform CSD recordings in the sleep-deprived awake non-anesthetized rat, using non-invasive techniques for CSD induction, such as optogenetics [69]. In addition, assessment of additional migraine surrogates might further underscore the relevance of our findings for migraine, such as monitoring of face grimacing [70], and measurement of blood levels of adenosine, melatonin or serotonin - factors that are important in migraine and might mediate the effect of sleep deprivation on CSD. Finally, future experiments that confirm our results in mutant

mice carrying human migraine mutations, such as FHM, and/or in female rodents, could further underscore the clinical relevance of our findings.

Conclusions

Primary headaches and sleeping problems are highly prevalent and cause considerable social and familial challenges. Sleep disorders and migraine seem to share pathophysiological pathways with a bidirectional influence, making it difficult to discern cause and effect. This study shows that acute sleep deprivation enhances CSD susceptibility, similar to other migraine promoting factors such as female gonadal hormones or genetic mutations. Acute sleep deprivation increases CSD frequency during topical KCl application and decreases the electrical threshold of CSD upon electrical stimulation. Furthermore, our results show that partial *chronic* sleep restriction/fragmentation by VLPO-lesioning, with predominant loss of NREM sleep, does not affect CSD susceptibility. These findings further underscore the importance of CSD as a migraine substrate, and open up new potential therapeutic avenues, suggesting that headache management should identify and treat associated sleep disorders.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s10194-020-01155-w>.

Additional file 1 : Figure 1. Acute sleep deprivation: Duration of first CSD. Duration of the first CSD was not reduced after 12 h or 6 h of sleep deprivation. Each circle represents the results of an individual rat. All controls (6 h controls and 12 h controls) were pooled for statistical analysis, as no significant difference was found between the two control groups. **Figure 2.** Acute sleep deprivation: Cumulative duration of CSDs. Cumulative duration of CSDs was not reduced after 12 h or 6 h of sleep deprivation. Each circle represents the results of an individual rat. All controls (6 h controls and 12 h controls) were pooled for statistical analysis, as no significant difference was found between the two control groups. **Figure 3.** Duration of first CSD and cumulative duration of CSDs in VLPO-lesioned rats. Duration of first CSD (**A**) and cumulative duration of CSDs upon topical continuous KCl (**B**) were not altered in rats after chronic sleep deprivation, 6 or 12 weeks after lesioning of the ventrolateral preoptic nucleus. The x-axis indicates the number of intact VLPO neurons after the lesioning procedure. Each circle represents the results of an individual rat. The number of VLPO neurons for sham animals was set to 800.

Abbreviations

ATP: Adenosine triphosphate; CADASIL: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CSD: Cortical spreading depolarization; DC: Extracellular steady; NREM: Nonrapid-eye movement; REM: Rapid-eye movement; VLPO: Ventrolateral preoptic nucleus

Acknowledgements

Not applicable.

Authors' contributions

AN: Conception of the study; Acquisition, analysis and interpretation of data; Drafting and revising the manuscript. JLS: Conception of the study; Acquisition, analysis and interpretation of data. TH: Acquisition, analysis and interpretation of data. ESY: Acquisition, analysis and interpretation of data. IR:

Acquisition, analysis of data. AA: Acquisition, analysis of data. LSG: Acquisition, analysis of data. LP: Acquisition, analysis of data. NY: Acquisition, analysis of data. NC: Conception of the study; Design of the study; Revision of the manuscript. RV: Conception of the study; Design of the study; Revision of the manuscript. NLC: Conception of the study; Design of the study; Revision of the manuscript. CA: Conception of the study; Design of the study; Analysis and interpretation of data; Revision of the manuscript. PM: Conception of the study; Revision of the manuscript. MAM: Conception of the study; Design of the study; Analysis and interpretation of data; Revision of the manuscript. KEH: Conception of the study; Design of the study; Analysis and interpretation of data; Drafting and revising the manuscript. The author(s) read and approved the final manuscript.

Funding

This work was funded in part by the American Heart Association (10SDG2610275, KEH; 10SDG2600218, IA), the Massachusetts General Hospital (Clafin Distinguished Award, KEH).

This work was funded in part by the Department of Clinical and Molecular Medicine, Sapienza University of Rome.

Availability of data and materials

Dataset available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All experimental procedures were carried out in accordance with the Guide for Care and Use of Laboratory Animals (NIH Publication No. 85–23, 1996), and were approved by the institutional review board (MGH Subcommittee on Research Animal Care, SRAC) and Institutional Animal Care and Use Committee of Beth Israel Deaconess Medical Center.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA. ²Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy. ³Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ⁴Department of Pathology, Boston Children's Hospital, Boston, MA, USA. ⁵Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ⁶Department of Radiology, and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ⁷Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.

Received: 19 March 2020 Accepted: 1 July 2020

Published online: 06 July 2020

References

- Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, Group AA (2007) Migraine prevalence, disease burden, and the need for preventive therapy. *Neurology*. 68:343–349
- Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, Goadsby PJ, Lipton RB (2011) Disability, hrqol and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (ibms). *Cephalalgia*. 31:301–315
- Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five european countries: results from the international burden of migraine study (IBMS). *J Headache Pain*. 13:361–378
- GBD. Disease and injury incidence and prevalence collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet* 390(10100):1211–1259
- Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z (2018) Migraine is first cause of disability in under 50s: will health politicians now take notice? *J Headache Pain* 19(1):17
- Manack AN, Buse DC, Lipton RB (2011) Chronic migraine: epidemiology and disease burden. *Curr Pain Headache Rep* 15:70–78
- Bigal ME, Lipton RB (2008) Concepts and mechanisms of migraine chronification. *Headache*. 48:7–15
- Odegard SS, Engstrom M, Sand T, Stovner LJ, Zwart JA, Hagen K (2010) Associations between sleep disturbance and primary headaches: the third Nord-Trøndelag health study. *J Headache Pain*. 11:197–206
- Wober C, Wober-Bingol C (2010) Triggers of migraine and tension-type headache. *Handb Clin Neurol* 97:161–172
- Reynolds AC, Banks S (2010) Total sleep deprivation, chronic sleep restriction and sleep disruption. *Prog Brain Res* 185:91–103
- Aguggia M, Cavallini M, Divito N, Ferrero M, Lentini A, Montano V, Tinebra MC, Saracco MG, Valfre W (2011) Sleep and primary headaches. *Neurol Sci* 32(Suppl 1):S51–S54
- Rains JC, Poceta JS (2012) Sleep-related headaches. *Neurol Clin* 30:1285–1298
- Bigal ME, Lipton RB (2009) What predicts the change from episodic to chronic migraine? *Curr Opin Neurol* 22:269–276
- Calhoun AH, Ford S (2007) Behavioral sleep modification may revert transformed migraine to episodic migraine. *Headache*. 47:1178–1183
- Guieu R, Devaux C, Henry H, Bechis B, Pouget J, Mallet D, Sampieri F, Juin M, Gola R, Rochat H (1998) Adenosine and migraine. *Can J Neurol Sci* 25(1): 55–58
- Leão AA (1944) Spreading depression of activity in cerebral cortex. *J Neurophysiol* 7:359–390
- Pietrobon D, Moskowitz MA (2013) Pathophysiology of migraine. *Annu Rev Physiol* 75:365–391
- Eikermann-Haerter K, Dilekoz E, Kudo C, Savitz SI, Waeber C, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2009) Genetic and hormonal factors modulate spreading depression and transient hemiparesis in mouse models of familial hemiplegic migraine type 1. *J Clin Invest* 119:99–109
- Eikermann-Haerter K, Yuzawa I, Dilekoz E, Joutel A, Moskowitz MA, Ayata C (2011) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome mutations increase susceptibility to spreading depression. *Ann Neurol* 69:413–418
- Eikermann-Haerter K, Baum MJ, Ferrari MD, van den Maagdenberg AM, Moskowitz MA, Ayata C (2009) Androgenic suppression of spreading depression in familial hemiplegic migraine type 1 mutant mice. *Ann Neurol* 66:564–568
- Lindquist BE, Shuttleworth CW (2012) Adenosine receptor activation is responsible for prolonged depression of synaptic transmission after spreading depolarization in brain slices. *Neuroscience*. 223:365–376
- Lindquist BE, Shuttleworth CW (2017) Evidence that adenosine contributes to Leao's spreading depression in vivo. *J Cereb Blood Flow Metab* 37(5): 1656–1669
- Delaruelle Z, Ivanova TA, Khan S, Negro A, Ornello R, Raffaelli B, Terrin A, Mitsikostas DD, Reuter U (2018) European Headache Federation School of Advanced Studies (EHF-SAS). Male and Female Sex Hormones in Primary Headaches. *J Headache Pain* 19(1):117
- Tobler I, Jaggi K (1987) Sleep and eeg spectra in the Syrian hamster (*mesocricetus auratus*) under baseline conditions and following sleep deprivation. *J Comp Physiol A* 161:449–459
- Andress-Rothrock D, King W, Rothrock J (2010) An analysis of migraine triggers in a clinic-based population. *Headache*. 50:1366–1370
- Lu J, Greco MA, Shiromani P, Saper CB (2000) Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. *J Neurosci* 20(10): 3830–3842
- Vetrivelan R, Fuller PM, Yokota S, Lu J, Saper CB (2012) Metabolic effects of chronic sleep restriction in rats. *Sleep*. 35(11):1511–1520
- Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. *Ann Neurol* 59:652–661
- Kelman L (2007) The triggers or precipitants of the acute migraine attack. *Cephalalgia*. 27:394–402
- Hauge AW, Kirchmann M, Olesen J (2011) Characterization of consistent triggers of migraine with aura. *Cephalalgia*. 31:416–438
- Hansen JM, Hauge AW, Ashina M, Olesen J (2011) Trigger factors for familial hemiplegic migraine. *Cephalalgia*. 31:1274–1281

32. Haque B, Rahman KM, Hoque A, Hasan AT, Chowdhury RN, Khan SU, Alam MB, Habib M, Mohammad QD (2012) Precipitating and relieving factors of migraine versus tension type headache. *BMC Neurol* 12:82
33. Wang J, Huang Q, Li N, Tan G, Chen L, Zhou J (2013) Triggers of migraine and tension-type headache in China: a clinic-based survey. *Eur J Neurol* 20: 689–696
34. Houle TT, Butschek RA, Turner DP, Smitherman TA, Rains JC, Penzien DB (2012) Stress and sleep duration predict headache severity in chronic headache sufferers. *Pain*. 153:2432–2440
35. Kelman L, Rains JC (2005) Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. *Headache* 45:904–910
36. Faraguna U, Nelson A, Vyazovskiy WV, Cirelli C, Tononi G (2010) Unilateral cortical spreading depression affects sleep need and induces molecular and electrophysiological signs of synaptic potentiation in vivo. *Cereb Cortex* 20: 2939–2947
37. Sancisi E, Cevoli S, Vignatelli L, Nicodemo M, Pierangeli G, Zanigni S, Grimaldi D, Cortelli P, Montagna P (2010) Increased prevalence of sleep disorders in chronic headache: a case-control study. *Headache*. 50:1464–1472
38. Karthik N, Kulkarni GB, Taly AB, Rao S, Sinha S (2012) Sleep disturbances in 'migraine without aura'—a questionnaire based study. *J Neurol Sci* 321:73–76
39. Seidel S, Hartl T, Weber M, Mattery S, Paul A, Riederer F, Gharabaghi M, Wöber-Bingöl C, Wöber C; PAMINA Study Group. Quality of sleep, fatigue and daytime sleepiness in migraine - a controlled study. *Cephalalgia*. 2009; 29:662–9
40. Palma JA, Urrestarazu E, Iriarte J (2013) Sleep loss as risk factor for neurologic disorders: a review. *Sleep Med* 14:229–236
41. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA (2007) The effects of sleep deprivation on pain inhibition and spontaneous pain in women. *Sleep*. 30:494–505
42. Vyazovskiy WV, Olcese U, Lazimy YM, Faraguna U, Esser SK, Williams JC, Cirelli C, Tononi G (2009) Cortical firing and sleep homeostasis. *Neuron*. 63(6):865–878
43. Kreuzer P, Langguth B, Popp R, Raster R, Busch V, Frank E, Hajak G, Landgrebe M (2011) Reduced intra-cortical inhibition after sleep deprivation: a transcranial magnetic stimulation study. *Neurosci Lett* 493(3):63–66
44. Bettendorff L, Sallanon-Moulin M, Touret M, Wins P, Margineanu I, Schoffeniels E (1996) Paradoxical sleep deprivation increases the content of glutamate and glutamine in rat cerebral cortex. *Sleep*. 19(1):65–71
45. Tadavarty R, Rajput PS, Wong JM, Kumar U, Sastry BR (2011) Sleep-deprivation induces changes in GABA(B) and mGlu receptor expression and has consequences for synaptic long-term depression. *PLoS One* 6(9):e24933
46. Pietrobon D, Moskowitz MA (2014) Chaos and commotion in the wake of cortical spreading depression and spreading Depolarizations. *Nat Rev Neurosci* 15(6):379–393
47. Dworak M, McCarley RW, Kim T, Kalinchuk AV, Basheer R (2010) Sleep and brain energy levels: ATP changes during sleep. *J Neurosci* 30:9007–9016
48. Ramanathan L, Gulyani S, Nienhuis R, Siegel JM (2002) Sleep deprivation decreases superoxide dismutase activity in rat hippocampus and brainstem. *Neuroreport*. 13:1387–1390
49. Singh R, Kiloung J, Singh S, Sharma D (2008) Effect of paradoxical sleep deprivation on oxidative stress parameters in brain regions of adult and old rats. *Biogerontology*. 9:153–162
50. Hohoff C, Marziniak M, Lesch KP, Deckert J, Sommer C, Mössner R (2007) An adenosine A2A receptor gene haplotype is associated with migraine with aura. *Cephalalgia*. 27(2):177–181
51. Lindquist BE, Shuttleworth CW (2014) Spreading depolarization-induced adenosine accumulation reflects metabolic status in vitro and in vivo. *J Cereb Blood Flow Metab* 34(11):1779–1790
52. Leenaars CCH, Savelyev SA, Van der Mierden S, Joosten RNJMA, Dematteis M, Porkka-Heiskanen T, Feenstra MGP Intracerebral Adenosine During Sleep Deprivation: A Meta-Analysis and New Experimental Data *J Circadian Rhythms* 2018;16:11
53. Masruha MR, de Souza Vieira DS, Minetti TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF (2008) Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. *J Headache Pain*. 9:221–224
54. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gögenur I (2011) Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. *J Pineal Res* 51:270–277
55. Ebert E, Hanke W, Wiedemann M (1999) Fernandes de Lima VM. Biphasic effects of melatonin on the propagation of excitation waves in the chicken retina. *Neurosci Lett* 268:37–40
56. le Grand SM, Patumraj S, Phansuwan-Pujito P, Srikiatkachorn A (2006) Melatonin inhibits cortical spreading depression-evoked trigeminal nociception. *Neuroreport*. 17:1709–1713
57. Peñalva RG, Lancel M, Flachskamm C, Reul JM, Holsboer F, Linthorst AC (2003) Effect of sleep and sleep deprivation on serotonergic neurotransmission in the hippocampus: a combined in vivo microdialysis/EEG study in rats. *Eur J Neurosci* 17(9):1896–1906
58. Alfaro-Rodríguez A, González-Piña R, González-Maciel A, Arch-Tirado E (2006) Serotonin and 5-hydroxy-indole-acetic acid contents in dorsal raphe and suprachiasmatic nuclei in normal, malnourished and rehabilitated rats under 24 h of sleep deprivation. *Brain Res* 1110(1):95–101
59. Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, Cui N, Middleton B, Ackermann K, Kayser M, Thumser AE, Raynaud FI, Skene DJ (2014) Effect of sleep deprivation on the human metabolome. *Proc Natl Acad Sci U S A* 111(29):10761–10766
60. Elmenhorst D, Kroll T, Matusch A, Bauer A (2012) Sleep deprivation increases cerebral serotonin 2A receptor binding in humans. *Sleep*. 35(12):1615–1623
61. Kilic K, Karatas H, Dönmez-Demir B, Eren-Kocak E, Gursoy-Ozdemir Y, Can A, Petit JM, Magistretti PJ, Dalkara T (2018) Inadequate brain glycogen or sleep increases spreading depression susceptibility. *Ann Neurol* 83(1):61–73
62. Kudo C, Toyama M, Boku A, Hanamoto H, Morimoto Y, Sugimura M, Niwa H (2013) Anesthetic effects on susceptibility to cortical spreading depression. *Neuropharmacology*. 67:32–36
63. von Economo C (1930) Sleep as a problem of localization. *J Nerv Ment Dis* 71:249–259
64. Szymusiak R, Gvilia, McGinty D (2007) Hypothalamic control of sleep. *Sleep Med* 8(4):291–301
65. Yang QZ, Hatton GI (1997) Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites. *Brain Res* 773(1–2):162–172
66. Steiner TL, Alam MN, Gong H, Szymusiak R, McGinty D (1999) Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. *Brain Res* 840(1–2):138–147
67. Meerlo P, de Bruin EA, Strijkstra AM, Daan S (2001) A social conflict increases EEG slow-wave activity during subsequent sleep. *Physiol Behav* 73(3):331–335
68. Balkaya M, Seidel JL, Sadeghian H, Qin T, Chung DY, Eikermann-Haerter K, van den Maagdenberg AMJM, Ferrari MD, Ayata C (2019) Relief following chronic stress augments spreading depolarization susceptibility in familial hemiplegic migraine mice. *Neuroscience*. 415:1–9
69. Böhm M, Chung DY, Gómez CA, Qin T, Takizawa T, Sadeghian H, Sugimoto K, Sakadžić S, Yaseen MA, Ayata C. Neurovascular coupling during optogenetic functional activation: Local and remote stimulus-response characteristics, and uncoupling by spreading depression. *J Cereb Blood Flow Metab*. 2020;40(4):808–822
70. Sotocinal SG, Sorge RE, Zaloum A, Tuttle AH, Martin LJ, Wieskopf JS, Mapplebeck JC, Wei P, Zhan S, Zhang S, McDougall JJ, King OD, Mogil JS (2011) The rat grimace scale: a partially automated method for quantifying pain in the laboratory rat via facial expressions. *Mol Pain* 7:55

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

